OCT 04, 2022 3:00 AM PDT

The NCI Welcomes First Woman Director: Monica M. Bertagnolli, MD

WRITTEN BY: Katie Kokolus

Monica M. Bertagnolli, M.D. Brigham and Women's Hospital. Photo Credit: NIH (https://www.nih.gov/about-nih/who-we-are/nih-director/statements/appointment-dr-monica-bertagnolli-director-national-cancer-institute)

In August, President Biden announced his intention to appoint Dr. Monica M. Bertagnolli as the newest director of the National Cancer Institute (NCI).  Yesterday, Bertagnolli began her tenure as the 16th NCI director and , notably, the first woman to take on this crucial role overseeing the largest center under the National Institutes of Health (NIH) umbrella.  Bertagnolli specializes in treating patients with gastrointestinal cancers and soft tissue sarcomas.  She has led a prolific career in which, beyond treating cancer patients, she has excelled in training translational researchers and advancing research to understand cancer better and improve survivorship. 

Bertagnolli attended Princeton University as an undergraduate and received her medical degree from the University of Utah.  After medical school, she completed a residency at Brigham and Woman’s Hospital in Boston, Massachusetts.  Bertagnolli also worked as an attending surgeon at New York Presbyterian Hospital–Cornell and as an associate surgeon at the Strang Cancer Prevention Center.  Before her recruitment to the NCI, Bertagnolli served as a Professor of Surgery at Harvard Medical School and a surgical oncologist at Brigham and Woman’s Hospital.  Additionally, she practiced with the Gastrointestinal Cancer Treatment and Sarcoma Centers at Dana-Farber Cancer Institute

Bertagnolli’s research program focuses on the Adenomatous Polyposis Coli (APC) gene, a well-established regulator of colorectal tumor development.  APC gene mutation can result in a serious disorder called Familial Adenomatous Polyposis (FAP).  FAP is a hereditary condition characterized by abnormal growth of polyps forming on tissues in the colon and rectum.  FAP remains a serious risk factor associated with colorectal cancer, and Bertagnolli’s research uses mouse models of the disease to understand how alterations in APC accelerate or mitigate, cancer risk.

Some of the discoveries made in the Bertagnolli laboratory include associating overexpression of an enzyme called Cox-2 with tumor development, uncovering the role of estrogen receptor signaling in colon cancer formation, correlating BRAF mutations with poor colon cancer prognosis, and improving prognostic staging criteria for colon cancer by evaluating lymph nodes and tumor deposits

Biden’s announcement to appoint Bertagnolli noted how she would serve as a powerful voice for cancer patients in support of the Cancer Moonshot, one of the President’s signature initiatives.  Additionally, the White House indicated that Bertagnolli’s experiences would help her advance health care in rural and remote communities.  Indeed, her research record indicates her well suited to expand the inclusivity of cancer care and prevention to these populations.   

As Dr. Bertagnolli takes the helm as the first woman director at the NCI, she will inspire future generations of translational cancer researchers!  I look forward to seeing how she transforms a new era of cancer research!

 

Sources: White House, ASCO, NIH, Harvard, NEJM, Cancer Res (Mahmoud), Carcinogenesis, Cancer Res (Boolbal), Clin Cancer Res, Annal Oncol, JCO Oncol Pract

About the Author
PhD
PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
AUG 24, 2022
Immunology
Immune Cells Can Use 'Waste' as a Powerful Fuel
AUG 24, 2022
Immune Cells Can Use 'Waste' as a Powerful Fuel
T cells are on the front lines of the immune system, monitoring the body for pathogens, and springing into action when t ...
SEP 28, 2022
Drug Discovery & Development
Impact of In Vivo Controls on Therapeutic Drug Development
SEP 28, 2022
Impact of In Vivo Controls on Therapeutic Drug Development
The significance of antibody based in vivo studies   For both research and therapeutic purposes, antibodies ca ...
OCT 10, 2022
Cancer
Experimental Drug Can Create Targets for Cancer-Killing Drugs
OCT 10, 2022
Experimental Drug Can Create Targets for Cancer-Killing Drugs
Immunotherapies continue to expand the cancer treatment landscape, providing new and exciting approaches to treat tumors ...
NOV 02, 2022
Clinical & Molecular DX
New Genetic Variants Identified as Risk Factors for Ovarian Cancer
NOV 02, 2022
New Genetic Variants Identified as Risk Factors for Ovarian Cancer
Ovarian cancer is a complex disease resulting from mutated cells in the ovaries. As the cells multiply, they can invade ...
NOV 09, 2022
Genetics & Genomics
Want to Study Copy Number Alterations in Cells? Bring MACHETE
NOV 09, 2022
Want to Study Copy Number Alterations in Cells? Bring MACHETE
Sure, MACHETE is a cool name, but the researchers that developed the technique are hoping people don't focus solely on t ...
NOV 13, 2022
Microbiology
A Cancer-Linked Microbe Can Use a Dietary Nutrient to Survive
NOV 13, 2022
A Cancer-Linked Microbe Can Use a Dietary Nutrient to Survive
The microbes in the human gastrointestinal tract, known as the gut microbiome, have a significant impact on out health a ...
Loading Comments...